^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD36 stimulant

    Related drugs:
    18d
    Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment. (PubMed, NPJ Precis Oncol)
    We have developed VT1021 that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). Our studies identified CD36 and CD47 as dual biomarkers that can be used as patient stratifying tools and prognostic biomarkers for VT1021 treatment.
    Journal
    |
    CD47 (CD47 Molecule) • CD36 (thrombospondin receptor)
    |
    VT1021
    7ms
    Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors. (PubMed, Commun Med (Lond))
    VT1021 is safe and well-tolerated in patients with solid tumors in a phase I expansion study. VT1021 has advanced to a phase II/III clinical study in glioblastoma (NCT03970447).
    P1 data • Journal • Metastases
    |
    THBS1 (Thrombospondin 1)
    |
    VT1021